Axial Biotech, Inc. is focused on the use of genetics and the development of minimally invasive, motion preserving implants to advance the diagnosis and treatment of diseases and deformities of the human spine. Axial is the first company to pursue DNA-based pre-symptomatic and prognostic tests for common spinal conditions which will augment current clinical and surgical practices.
Deal Flow
Fundings
| Closing Date | Round | Amount |
|---|---|---|
| 03/17/2008 | Unattributed | $7,000,000 |
| 03/01/2008 | Series B | $6,000,000 |
| 10/01/2006 | Unattributed | $650,000 |
| 01/01/2005 | Series A | $4,100,000 |
Mergers & Acquisitions
Public Offerings
Company Snapshot
Yes
Biotechnology | Diagnostics
2003
Active
Not Assigned
$750,000
$26,050,000
20
20
2009 Innovation Award
Key People
-
Lesa Nelson
VP of Clinical Operations
-
Rina Wolf
VP of Reimbursement and Regulatory Affairs
-
Joe Ross
VP of Strategic Initiatives
-
John Climaco
CEO and President
-
Eric Olson
Executive VP of Sales and Marketing






